Loading...

And this team from MIT and, I'm sorry, it was a team from MIT and Harvard Medical School, they've now created a more effective way to engineer these cells that reduce the chances of the body's immune system rejecting them. And immune rejection has been one of the biggest obstacles of cell-based therapies. And this innovation could make it possible to produce off-the-shelf treatments that are available immediately after diagnosis rather than waiting weeks for custom engineered cells.